Primary mosaic neuroendocrine/adenocarcinoma of the prostate

Mosaic cancers are composed of two or several genetically different cell populations. Mosaicism has been considered to be rare among solid malignancies, with the exception of the germ cell tumours. Although neuroendocrine foci have been described within adenocarcinomas of the prostate, they have been interpreted as an advanced stage of the disease and the clinical relevance of the histological finding has remained uncertain. In this communication we give a summary on neuroendocrine prostate cancers. We recall the results of a recent single centre cohort of patients with neuroendocrine prostate cancer that showed higher incidence and better prognosis as expected by the literature. We show for the first time histological images of a primary mosaic neuroendocrine/adenocarcinoma of the prostate. A model explaining the development of mosaic cancers in the prostate is presented. Finally, we discuss the phenomenon of mosaicism related to prostate cancer in general.

Neuroendocrine; Mosaic; Mosaicism; Prostate cancer; Immunohistochemistry

[1] Machiela MJ. Mosaicism, aging and cancer. Current Opinion in Oncology. 2019; 31: 108–113.

[2] Thorpe J, Osei-Owusu IA, Avigdor BE, Tupler R, Pevsner J. Mosaicism in human health and disease. Annual Review of Genetics. 2020; 54: 487–510.

[3] Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Molecular Cancer. 2017; 16: 41.

[4] Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nature Reviews Urology. 2021; 18: 79–92.

[5] Moreno CS, Winham CL, Alemozaffar M, Klein ER, Lawal IO, Abiodun-Ojo OA, et al. Integrated genomic analysis of primary prostate tumor foci and corresponding lymph node metastases identifies mutations and pathways associated with metastasis. Cancers. 2023; 15: 5671.

[6] Zaffuto E, Pompe R, Zanaty M, Bondarenko HD, Leyh-Bannurah S, Moschini M, et al. Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis. Clinical Genitourinary Cancer. 2017; 15: e793–e800.

[7] Honn KV, Aref A, Chen YQ, Cher ML, Crissman JD, Forman JD, et al. Prostate cancer—old problems and new approaches. (Part II. diagnostic and prognostic markers, pathology and biological aspects). Pathology Oncology Research. 1996; 2: 191–211.

[8] Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. American Journal of Clinical and Experimental Urology. 2014; 2: 273–285.

[9] Li J, Wang Z. The pathology of unusual subtypes of prostate cancer. Chinese Journal of Cancer Research. 2016; 28: 130–143.

[10] Kránitz N, Szepesváry Z, Kocsis K, Kullmann T. Neuroendocrine cancer of the prostate. Pathology & Oncology Research. 2020; 26: 1447–1450.

[11] Kullmann T, András S, Noémi K, Zsolt S. Neuroendocrine cancer of the prostate. Two case reports. Journal of Men’s Health. 2022; 18: 65.

[12] Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration resistant neuroendocrine prostate cancer. Nature Medicine. 2016; 22: 298–305.

[13] Kumar K, Ahmed R, Chukwunonso C, Tariq H, Niazi M, Makker J, et al. Poorly differentiated small-cell-type neuroendocrine carcinoma of the prostate: a case report and literature review. Case Reports in Oncology. 2018; 11: 676–681.

[14] Ma X, Jiang X, Yang X. Mechanisms of castration resistant prostate cancer formation and progression through neuroendocrine differentiation. Journal of Men’s Health. 2021; 17: 17–21.

[15] Blackwood JK, Williamson SC, Greaves LC, Wilson L, Rigas AC, Sandher R, et al. In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells. The Journal of Pathology. 2011; 225: 181–188.

[16] Al Salhi Y, Sequi MB, Valenzi FM, Fuschi A, Martoccia A, Suraci PP, et al. Cancer stem cells and prostate cancer: a narrative review. International Journal of Molecular Sciences. 2023; 24: 7746.

[17] Beltran H, Rickman DS, Park K, Chae SS, Sboner A, Macdonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discovery. 2011; 1: 487–495.

[18] Lobo J, Gillis AJM, Jerónimo C, Henrique R, Looijenga LHJ. Human germ cell tumors are developmental cancers: impact of epigenetics on pathobiology and clinic. International Journal of Molecular Sciences. 2019;20: 258.

[19] Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New England Journal of Medicine. 2015; 373: 737–746.

[20] Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. New England Journal of Medicine. 2022; 386: 1132–1142.

[21] Tamás K, Károly K, Adél A, Noémi K, Ágnes H, Zsolt S. Optimisation of second line antihormonal treatment for castration resistant metastatic prostate cancer. Journal of Men’s Health. 2022; 18: 93.

[22] Ton AT, Singh K, Morin H, Ban F, Leblanc E, Lee J, et al. Dual-inhibitors of N-Myc and AURKA as potential therapy for neuroendocrine prostate cancer. International Journal of Molecular Sciences. 2022; 21: 8277.

[23] Bakht MK, Yamada Y, Ku SY, Venkadakrishnan VB, Korsen JA, Kalidindi TM, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nature Cancer. 2023; 4: 699–715.

[24] Hurst R, Meader E, Gihawi A, Rallapalli G, Clark J, Kay GL, et al. Microbioms of urine and the prostate are linked to human prostate cancer risk groups. European Urology Oncology. 2022; 5: 412–419.

[25] Kobayashi T, Hashiya T, Ikehata Y, Horie S. Genetic association of mosaic loss of chromosome Y with prostate cancer in men of European and East Asian ancestries: a mendelian randomization study. Frontiers in Aging. 2023; 4: 1176451.

[26] Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al.; ESMO Guidelines Committee. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020; 31: 844–860.